## COX-2/5-LOX-IN-3

| Cat. No.: | $\mathrm{HY}-147951$ |
| :--- | :--- |
| CAS No.: | $2481484-51-7$ |
| Molecular Formula: | $\mathrm{C}_{17} \mathrm{H}_{16} \mathrm{ClN}_{3} \mathrm{O}_{2} \mathrm{~S}$ |
| Molecular Weight: | 361.85 |
| Target: | COX ; Lipoxygenase |
| Pathway: | Immunology/Inflammation; Metabolic Enzyme/Protease |
| Storage: | Please store the product under the recommended conditions in the Certificate of |
|  | Analysis. |



## BIOLOGICAL ACTIVITY

Description
$\mathrm{IC}_{50}$ \& Target

| 5-LOX | COX-2 | COX-1 |
| :---: | :---: | :---: |
| $4.33 \mu \mathrm{M}\left(\mathrm{IC}_{50}\right)$ | $5.45 \mu \mathrm{M}\left(\mathrm{IC}_{50}\right)$ | $45.73 \mu \mathrm{M}\left(\mathrm{IC}_{50}\right)$ |

In Vivo
COX-2/5-LOX-IN-3 (compound 5b) is a potent and dual COX-2/5-LOX inhibitor with $\mathrm{IC}_{50}$ values of $45.73,5.45$ and $4.33 \mu \mathrm{M}$ for COX-1, COX-2, and 5-LOX, respectively. COX-2/5-LOX-IN-3 has the potential for the research of inflammation diseases ${ }^{[1]}$.

## $4.33 \mu \mathrm{M}\left(\mathrm{IC}_{50}\right)$

COX-2/5-LOX-IN-3 (compound 5b) (p.o.; male Sprague Dawley rats) shows anti-inflammatory activities in vivo ${ }^{[1]}$.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| Animal Model: | Male Sprague Dawley rats ${ }^{[1]}$ |
| :--- | :--- |
| Dosage: | $2.622 \times 10^{-5} \mathrm{~mol} / \mathrm{kg}$ |
| Administration: | Oral administration |
| Result: | The percentage inhibition of edema (\%l) reached 58.77 |

## REFERENCES

[1]. Qandeel NA, et al. Synthesis, in vivo anti-inflammatory, COX-1/COX-2 and 5-LOX inhibitory activities of new 2,3,4-trisubstituted thiophene derivatives. Bioorg Chem. 2020 Sep;102:103890

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898 Fax: 609-228-5909 E-mail:tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

